Email

Print

Tweet

Digg!

Del.icio.us

DALLAS and NEW YORK, Dec. 10, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has entered into definitive agreements with existing and new accredited investors to sell, in a registered direct offering, an aggregate of approximately 2.3 million shares of its common stock at a price of$2.55 per share for aggregate gross proceeds of $6.0 million.  Additionally, at the closing, Access will issue to the investors warrants to purchase, in the aggregate, approximately 0.7 million shares of common stock at a price of $3.06 per share, which warrants are exercisable immediately for a term of 5 years from the closing date.  The initial closing of the offering is expected to take place subject to the satisfaction of customary closing conditions.

“In addition to providing Access capital to support the commercial launch of MuGard, this financing should prove to be a positive for Access investors as it also helps shore up our balance sheet for partnering discussions in our various programs,” stated Jeffrey B. Davis, President & CEO.  He continued, “This additional funding from current and new investors will provide a strong foundation to continue executing on our multifaceted strategy for moving valuable assets within the company forward.”
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Company Gains Traction With Top Healthcare Insurance Companies Less Than Two Months Into Full-Scale Lead Product Launch

Dallas, TX and New York, NY, December 9, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has made significant progress in obtaining MuGard reimbursements from various third-party payer networks.  Some of the national insurance reimbursements included several state plans from Blue Cross Blue Shield, Health Net, Caremark, Well Point Next Rx, Harvard Pilgrim and Medicaid.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Significant Step Validates Company’s Unique Value-Driven Strategy For Exploiting Multi-applicable Oral Drug Delivery Technology Platform

Dallas, TX and New York, NY, December 08, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major global pharmaceutical company to test Access’ oral insulin formulation based upon its proprietary vitamin B-12-based CobOral™ Drug Delivery Technology.  Access will provide CobOral insulin to the pharmaceutical company. Access anticipates completion and delivery of its CobOral insulin formulation to the pharmaceutical company by the end of the month.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

MuGard Website Features Video And Additional Written Clinician Feedback

Dallas, TX and New York, NY, December 3, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has updated its lead product website, www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.

The video can be found under the Testimonial section of the MuGard website (www.MuGard.com), or by clicking on the following link:  www.MuGard.com/testimonials/.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Dallas, TX and New York, NY, November 11, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it will be presenting a poster today at the 10th Annual Diabetes Technology Meeting, entitled, “Preclinical Studies with Cobalamin™ Nanoparticles for Oral Drug Delivery of Insulin.”  The poster reviews the progress made by Access scientists in developing its proprietary oral insulin formulation. Access recently rebranded its oral drug delivery technology as CobOral^TM to reflect the advances made with the technology platform.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Dallas, TX and New York, NY, October 27, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into a pre-licensing feasibility agreement with a leading biopharmaceutical company to develop an oral formulation of an undisclosed prostate cancer compound utilizing its proprietary vitamin B-12-based CobOral™ Drug Delivery Technology.  Access will develop CobOral formulations for testing by the biopharma company. Though the terms of the agreement have not been disclosed, Access indicated that any successful formulation developed will be jointly owned by the Parties and subject to a subsequent full licensing agreement.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Furthered Cobalamin-Mediated Formulation Interest Leads to New Patent Filings And CobOral™ Branding

Dallas, TX and New York, NY

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company’s proprietary oral delivery technology.  The patents cover oral formulations of leading injectables, like bevacizumab (Avastin®), trastuzumab (Herceptin®), adalimumab (Humira®), etanercept (Enbrel®), insulin glargine (Lantus®), and many others.  In addition, Access rebranded its Cobalamin-mediated oral drug delivery technology as CobOral™ delivery technology.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Company Reaches Critical Milestone In North American MuGard Commercialization Process

DALLAS, TX and NEW YORK, NY, October 15, 2010

Access Pharmaceuticals, Inc. (OTC BB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.  In addition, the Company has received reimbursement for the prescriptions from leading health care providers. Through its consultants and specialty distribution partner, Access’ outreach to payor networks for MuGard prescription reimbursement is ongoing.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Patients Experienced 52% Reduction in Pain and Oral Discomfort; MuGard’s Ready-to-Use Formulation Well Accepted By 86% of Patients

DALLAS, TX and NEW YORK, NY, October 11, 2010

Access Pharmaceuticals, Inc. (OTC BB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year’s European Society of Medical Oncology Conference in Milan, Italy.   Some of the findings reported in the ESMO presentation included:

• MuGard provided a significant improvement and/or stabilization of oral mucositis lesions and symptoms of oral mucositis (OM) in more than 75% of cancer patients treated with radiotherapy/chemotherapy;

• Patients reported a 52% significant reduction in oral discomfort (oral pain and swallowing ability) in patients with pre-existing lesions of OM, and reported a substantial reduction in the use of pain medication;

• MuGard has a ready-to-use formulation that is well accepted by 86% of patients, as reported in this assessment program;

• No MuGard-related adverse reactions have been identified in clinical practice;

• MuGard represents a valuable therapeutic option in the treatment and prevention of OM in cancer patients undergoing radio/chemotherapy.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Proof-of-Principle Data for Proprietary CobaCyte™ Platform in siRNA

Dallas, TX and New York, NY, September 29, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.  As a result of the continued advancements made with its Cobalamin program, Access rebranded the targeted-drug delivery technology as CobaCyte™; and submitted additional patent applications for its improved CobaCyte formulations, including siRNA compositions.

Over the past months, Access’ CobaCyte siRNA application has shown significant promise.  In an in vitro siRNA transfection dose-response study, Access’ CobaCyte nanoparticle carriers loaded with an apoptosis-inducing siRNA molecule showed transfection activity in hard-to-transfect cell lines with potentially better toxicity profiles compared to other reagents. Further studies including in vivo gene-knockdown studies are planned. Additionally, Access has initiated a program whereby proprietary formulations of currently marketed chemotherapies will be developed and tested to assess CobaCyte’s ability to enhance drug pharmacokinetics and pharmacodynamics.
Read more »